Ligand id: 8985

Name: adriforant

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 79.1
Molecular weight 262.19
XLogP 1.61
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
ZPL-3893787 has reached Phase 2 clinical trial for evaluation as an antiinflammatory agent in patients with plaque psoriasis (see NCT02618616), and a Phase 1 in atopic dermatitis has been completed.
Mechanism Of Action and Pharmacodynamic Effects
Allergic inflammation is reported to be augmented via histamine H4 receptor activation [1]. In light of this H4 receptor antagonists would be expected to inhibit this effect,
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02618616 A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis Phase 2 Interventional Ziarco Pharma Ltd